Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
The company aims to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and glucagon-like peptide-1 (GLP-1) drugs.
BD will introduce Neopak Glass Prefillable Syringe manufacturing at its facility in Columbus, Nebraska.
Available in 1ml and 2.25ml formats, the platform is designed to support various formulation needs, including high...
Menkes disease is a rare X-linked recessive disorder caused by mutations in the ATP7A gene, resulting in impaired copper absorption and transport.
Zycubo is administered subcutaneously to restore copper balance and maintain appropriate copper levels in affected patients.
The FDA granted the approval based on the positive top line clinical efficacy results....
The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies will jointly oversee early-stage development of the antibody candidates. Following the initial stages, Novartis will assume responsibility for all further produc...
The application sought approval for Ebvallo as monotherapy in adult and paediatric patients aged two years and above with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have previously received at least one treatment, including anti-CD20 therapy.
The FDA’s CRL means the application cannot be approved in its current form.
...The facility forms a key component of the company’s $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments across the country. The new purpose-built, 35,000ft² facility marks the company’s fourth RLT facility in the US and is scheduled to become operational by 2029. Novartis claims that this site will boost it...
